Glucocorticoid receptor beta (GR-beta)

Glucocorticoid receptor beta (GR-beta) is a splice variant of the NR3C1 gene, distinguished from the classic GR-alpha isoform by a unique C-terminal sequence that prevents it from binding traditional glucocorticoids like cortisol or dexamethasone (Source 1.1.2, 1.4.1). Historically, it was characterized primarily as a dominant-negative inhibitor of GR-alpha, functioning by competing for DNA binding sites and forming inactive heterodimers that attenuate steroid-mediated gene regulation (Source 1.2.2, 1.3.1). Elevated expression of GR-beta is a key driver of glucocorticoid resistance in chronic inflammatory diseases such as severe asthma, rheumatoid arthritis, and ulcerative colitis (Source 1.2.1, 1.3.1). Recent studies have revealed that GR-beta also possesses intrinsic, GR-alpha-independent transcriptional activity, regulating genes involved in cell growth, migration, and survival, such as PTEN and GATA3 (Source 1.1.1, 1.4.2). This independent activity suggests that GR-beta may act as an oncogene in certain malignancies, including bladder and prostate cancers, where it promotes tumor progression (Source 1.4.1, 1.4.3). While traditional glucocorticoids do not bind GR-beta, the antagonist mifepristone (RU-486) has been shown to interact with it and modulate its transcriptional activity (Source 1.1.2, 1.3.5). Emerging therapeutic strategies focus on reducing GR-beta expression using antisense oligonucleotides or peptide nucleic acids, such as Sweet-P, to restore steroid sensitivity and inhibit oncogenic signaling (Source 1.4.1, 1.4.2).

Other names

Nuclear receptor subfamily 3 group C member 1 isoform betahGR-betahGRβGRβ

Dominant-negative inhibition of Glucocorticoid receptor alpha; Direct transcriptional regulation of target genes; Modulation of PI3K/Akt signaling pathway